未登录

L

Lingong Jiang

Naval Medical University

H指数:9

被引数:258

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial

立体定向体部放射治疗联合适应vNKT细胞疗法治疗胰腺癌：一项II期试验方案

IF2.3

2025-07-160

OA

ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer

ADJUPANC协议：一项关于胰腺癌辅助化疗与化学放疗比较的III期研究

Future Oncology

IF2.6

2025-06-290

PRE

Central-boost Ablative Radiation Therapy for Solid Tumors: Study Protocol of a Single-arm, Phase II Trial (CBART)

中央提升式烧蚀放射疗法治疗实体瘤：一项单臂、II期试验（CBART）的研究方案

Technology in Cancer Research & Treatment

IF2.8

2025-06-120

OA

Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer

转移性胰腺癌患者的原发性肿瘤和寡转移的立体定向放射治疗与单独的原发性肿瘤治疗

RADIATION ONCOLOGY

IF3.2

2024-08-192

OAAI

Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial

RADIOTHERAPY AND ONCOLOGY

IF5.3

2024-01-011

PRE

Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic cancer by deformable image registration

FRONTIERS IN ONCOLOGY

IF3.3

2023-01-301

OAAI

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial

ECLINICALMEDICINE

IF10

2023-01-017

OAAI

Protocol of the integrated boost to the dominant intraprostatic nodule in stereotactic body radiation therapy for localized prostate cancer

FUTURE ONCOLOGY

IF2.6

2022-12-121

PRE

Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single-arm, phase 2 trial

RADIOTHERAPY AND ONCOLOGY

IF5.3

2021-09-017

PRE

Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy

FRONTIERS IN ONCOLOGY

IF3.3

2021-06-084

OAAI

Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2020-12-1416

OAAI

Posttreatment Immune Parameter Predictor for Cancer Control in Stage I Non-small Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiation Therapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2017-10-012

OAAI

Phosphorothioate-modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy

MOLECULAR MEDICINE REPORTS

IF3.5

2017-06-149

OAAI